352 related articles for article (PubMed ID: 25326459)
1. Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
Schwab N; Schneider-Hohendorf T; Wiendl H
Int Immunol; 2015 Jan; 27(1):47-53. PubMed ID: 25326459
[TBL] [Abstract][Full Text] [Related]
2. The link between VLA-4 and JC virus reactivation.
Monaco MC; Major EO
Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
[TBL] [Abstract][Full Text] [Related]
3. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
[TBL] [Abstract][Full Text] [Related]
4. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
5. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
6. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
Bennett JL
Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
Warnke C; Menge T; Hartung HP; Racke MK; Cravens PD; Bennett JL; Frohman EM; Greenberg BM; Zamvil SS; Gold R; Hemmer B; Kieseier BC; Stüve O
Arch Neurol; 2010 Aug; 67(8):923-30. PubMed ID: 20697042
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
[TBL] [Abstract][Full Text] [Related]
10. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
11. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
12. PML risk stratification using anti-JCV antibody index and L-selectin.
Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
[TBL] [Abstract][Full Text] [Related]
13. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
14. [Neuropathology of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy].
Kanda T
Brain Nerve; 2015 Jul; 67(7):891-901. PubMed ID: 26160817
[TBL] [Abstract][Full Text] [Related]
15. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
Khalili K; White MK; Lublin F; Ferrante P; Berger JR
Neurology; 2007 Mar; 68(13):985-90. PubMed ID: 17389301
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
Rossi F; Newsome SD; Viscidi R
Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
Hunt D; Giovannoni G
Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
20. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
